Journal of the Chinese Medical Association
Volume 73, Issue 3 , Pages 156-160 , March 2010

Hepatitis B Virus Reactivation After 23 Months of Rituximab-based Chemotherapy in an HBsAg-negative, Anti-HBs-positive Patient With Follicular Lymphoma

  • I-Cheng Lee

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • ,
  • Yi-Hsiang Huang

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
    • Corresponding Author InformationCorrespondence to: Dr Yi-Hsiang Huang, Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan, R.O.C.
    • ,
  • Chi-Jen Chu

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • ,
  • Pui-Ching Lee

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • ,
  • Han-Chieh Lin

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • ,
  • Shou-Dong Lee

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.

Received 30 June 2009 ,Accepted 23 December 2009.

References 

  1. Lee WM . Hepatitis B virus infection . N Engl J Med . 1997;337:1733–1745
  2. Yeo W , Johnson PJ . Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy . Hepatology . 2006;43:209–220
  3. Lok AS , Liang RH , Chiu EK , Wong KL , Chan TK , Todd D . Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study . Gastroenterology . 1991;100:182–188
  4. Lok AS , McMahon BJ . Chronic hepatitis B . Hepatology . 2007;45:507–539
  5. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma . N Engl J Med . 2002;346:235–242
  6. Chang H , Yeh HC , Su YC , Lee MH . Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma receiving chemotherapy containing rituximab . J Chin Med Assoc . 2008;71:579–582
  7. Han SM , Teng CL , Hwang GY , Chou G , Tsai CA . Primary splenic lymphoma associated with hemophagocytic lymphohis-tiocytosis complicated with splenic rupture . J Chin Med Assoc . 2008;71:210–213
  8. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al  Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab . J Clin Oncol . 2009;27:605–611
  9. Dervite I , Hober D , Morel P . Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab . N Engl J Med . 2001;344:68–69
  10. Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, et al  Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy . Blood . 2003;102:1930
  11. Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, et al  Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma . Ann Hematol . 2004;83:58–60
  12. Sarrecchia C , Cappelli A , Aiello P . HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb . J Infect Chemother . 2005;11:189–191
  13. Law JK , Ho JK , Hoskins PJ , Erb SR , Steinbrecher UP , Yoshida EM . Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations . Leuk Lymphoma . 2005;46:1085–1089
  14. Niscola P, Del Principe MI, Maurillo L, Venditti A, Buccisano F, Piccioni D, et al  Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy . Leukemia . 2005;19:1840–1841
  15. Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, et al  Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab . Intern Med . 2006;45:721–724
  16. Ozgonenel B , Moonka D , Savasan S . Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphoma . Am J Hematol . 2006;81:302
  17. Yamagata M, Murohisa T, Tsuchida K, Okamoto Y, Tsunoda S, Nakamura M, et al  Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab . Leuk Lymphoma . 2007;48:431–433
  18. Dillon R , Hirschfield GM , Allison ME , Rege KP . Fatal reactivation of hepatitis B after chemotherapy for lymphoma . BMJ . 2008;337:a423
  19. Wu JM , Huang YH , Lee PC , Lin HC , Lee SD . Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma . J Clin Gastroenterol . 2009;43:496–498
  20. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update . Hepatol Int . 2008;2:263–283
  21. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al  Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors . J Med Virol . 2000;62:299–307
  22. Lim ST, Fei G, Quek R, Lim LC, Lee LH, Yap SP, et al  The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis . Eur J Haematol . 2007;79:132–137
  23. Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, et al. Rituximab-related viral infections in lymphoma patients . Leuk Lymphoma . 2007;48:1307–1312
  24. He YF, Li YH, Wang FH, Jiang WQ, Xu RH, Sun XF, et al  The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma . Ann Hematol . 2008;87:481–485
  25. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, et al  Prophylaxis and treatment of hepatitis B in immunocompromised patients . Dig Liver Dis . 2007;39:397–408
  26. Hoofnagle JH . Reactivation of hepatitis B . Hepatology . 2009;49:S156–S165

PII: S1726-4901(10)70031-9

doi: 10.1016/S1726-4901(10)70031-9

Journal of the Chinese Medical Association
Volume 73, Issue 3 , Pages 156-160 , March 2010

Article Tools